Literature DB >> 11015134

Perfluorochemical elimination from the lungs: effect of initial dose.

C M Weis1, W W Fox, C M Philips, M R Wolfson, T H Shaffer.   

Abstract

Liquid-assisted ventilation with perfluorochemical (PFC) has been beneficial in a variety of respiratory diseases in animals and humans. Although PFC evaporation from the lungs is in part dependent on ventilation strategy and positioning, guidelines for initial and replacement dosing are unclear. We hypothesized that PFC evaporative loss over time is dependent on the size of the initial dose. Juvenile rabbits (n = 18) were ventilated using constant animal position and ventilator strategy. PFC (perflubron: LiquiVent ) was instilled endotracheally, using four groups with initial doses of 2, 6, 12, and 17 mL/kg. A previously described thermal detector that measures PFC in expired gas was used to calculate loss rate, residual perflubron in the lung, and volume loss as a % of initial fill volume. There was a significant dose, time, and dose-time interaction such that evaporative loss was dependent on initial PFC volume and time after fill (P < 0.05). Evaporative loss rate decreased earlier at lower doses. The percentage of initial volume lost to evaporation over time was inversely related to dose and could not be predicted by decreasing % PFC saturations, independent of dose. Evaporative loss should be considered to optimize both the application of PFC to the lung and replacement dosing during partial liquid ventilation. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015134     DOI: 10.1002/1099-0496(200010)30:4<324::aid-ppul9>3.0.co;2-7

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  1 in total

1.  Partial liquid ventilation: effects of positive end-expiratory pressure on perfluorocarbon evaporation from the lungs of anesthetized dogs.

Authors:  Stephan A Loer; Lothar A Schwarte; Michael A Pakulla; Olaf Picker; Thomas W L Scheeren
Journal:  Intensive Care Med       Date:  2003-02-08       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.